Patents by Inventor Krisztina Paal
Krisztina Paal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8946167Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.Type: GrantFiled: February 9, 2009Date of Patent: February 3, 2015Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
-
Publication number: 20100076008Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.Type: ApplicationFiled: February 9, 2009Publication date: March 25, 2010Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
-
Patent number: 7501455Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.Type: GrantFiled: March 17, 2004Date of Patent: March 10, 2009Assignee: Sicor, Inc.Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
-
Publication number: 20070232536Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.Type: ApplicationFiled: October 10, 2006Publication date: October 4, 2007Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
-
Patent number: 7119124Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.Type: GrantFiled: January 21, 2003Date of Patent: October 10, 2006Assignee: Human Rt.Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
-
Publication number: 20050282734Abstract: An optically clear, pharmaceutically acceptable aqueous composition comprising paclitaxel or a derivative thereof, serum albumin and a pharmaceutically acceptable vehicle, wherein the composition comprises no more than 10% organic solvent and has a pH of about 3.0 to about 4.8, is described. The serum albumin can be fatted or defatted, and the composition can optionally be lyophilized or optionally lyophilized and reconstituted. At least 70% of the paclitaxel is bound to serum albumin, the ratio of paclitaxel to albumin is at least about 1:5, and the concentration of paclitaxel is at least about 25 ?g/ml. Methods of making and using this composition an also provided.Type: ApplicationFiled: March 23, 2005Publication date: December 22, 2005Inventors: Tenshuk Kadima, Howard Kaplan, Robert Tuttle, Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
-
Publication number: 20050064028Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.Type: ApplicationFiled: March 17, 2004Publication date: March 24, 2005Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
-
Patent number: 6743826Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible; pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.Type: GrantFiled: April 27, 1999Date of Patent: June 1, 2004Assignee: Human RTInventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
-
Publication number: 20040014655Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.Type: ApplicationFiled: January 21, 2003Publication date: January 22, 2004Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
-
Patent number: 5811521Abstract: Multifunctional chemical reagents useful in cross-linking hemoglobin and having the capability of leaving two or more reaction sites available for further chemical reactions, after completion of the cross-linking process. These reagents are broadly defied as aromatic compounds comprising an aromatic nucleus including but not limited phenyl, biphenyl, naphthyl and binaphthyl, with at least four independently selected electronegative substituent groups bonded directly or indirectly to the aromatic nucleus.Type: GrantFiled: April 11, 1997Date of Patent: September 22, 1998Inventors: Ronald H. Kluger, Krisztina Paal